Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$27,000.00
Harnessing Radiation Therapy to Overcome Resistance to Immunotherapy in Soft Tissue Sarcomas
FY 2024-25
Summary
This study investigates the potential synergy between radiation therapy (RT) and STING (Stimulator of Interferon Genes) agonists to overcome treatment resistance in soft tissue sarcomas (STS). STS are aggressive, immune-suppressive tumours with limited therapeutic options, characterized by poor response to immunotherapies and high relapse rates. The project aims to determine if combining RT with STING therapy can enhance tumour clearance in pre-clinical murine models, particularly in STING-resistant models like KPP1053.Our research will use immune-competent mice with two distinct sarcoma models: TAO1+, which is STING-permissive, and KPP1053, a STING-resistant line. Mice will receive various hypofractionated RT doses (8, 24, 40 Gy) to explore dose-dependent immune responses (spanning low-dose RT to high-dose RT). STING therapy will be delivered using agonist E7766, with detailed immune profiling and molecular analyses conducted to assess changes in immune cell populations, tumour microenvironment (TME) modulation, and survival outcomes.Key objectives include identifying optimal RT dosing, determining the ideal sequence for STING administration, and evaluating molecular markers of tumour immune response. This research aims to understand whether RT can reprogram a cold TME into a more immunogenic hot state, increasing the effectiveness of STING agonists and reducing tumour progression.Findings from this study will provide critical insights into novel combination strategies to improve therapeutic outcomes in STS, potentially transforming the treatment landscape for this challenging cancer. By advancing knowledge of tumour-immune dynamics, the project will seek to inform clinical strategies, improving survival and quality of life for sarcoma patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529671
Name
Mahoney Logan
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Harnessing Radiation Therapy to Overcome Resistance to Immunotherapy in Soft Tissue Sarcomas
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Research; Combination Treatment; Immune Systems; Immunotherapy Agonistss; Preclinical Research; Radiation Therapy; Soft Tissue Sarcoma; Sting Pathway Therapy; Therapeutic Resistance; Tumour Microenvironment
Abstract
This study investigates the potential synergy between radiation therapy (RT) and STING (Stimulator of Interferon Genes) agonists to overcome treatment resistance in soft tissue sarcomas (STS). STS are aggressive, immune-suppressive tumours with limited therapeutic options, characterized by poor response to immunotherapies and high relapse rates. The project aims to determine if combining RT with STING therapy can enhance tumour clearance in pre-clinical murine models, particularly in STING-resistant models like KPP1053.Our research will use immune-competent mice with two distinct sarcoma models: TAO1+, which is STING-permissive, and KPP1053, a STING-resistant line. Mice will receive various hypofractionated RT doses (8, 24, 40 Gy) to explore dose-dependent immune responses (spanning low-dose RT to high-dose RT). STING therapy will be delivered using agonist E7766, with detailed immune profiling and molecular analyses conducted to assess changes in immune cell populations, tumour microenvironment (TME) modulation, and survival outcomes.Key objectives include identifying optimal RT dosing, determining the ideal sequence for STING administration, and evaluating molecular markers of tumour immune response. This research aims to understand whether RT can reprogram a cold TME into a more immunogenic hot state, increasing the effectiveness of STING agonists and reducing tumour progression.Findings from this study will provide critical insights into novel combination strategies to improve therapeutic outcomes in STS, potentially transforming the treatment landscape for this challenging cancer. By advancing knowledge of tumour-immune dynamics, the project will seek to inform clinical strategies, improving survival and quality of life for sarcoma patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mahoney, Logan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~